| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
Natural antioxidant
|
|---|---|
| ln Vitro |
Salvianolic acid Y exhibits protective properties against cell lesions induced by hydrogen peroxide (H2O2). In the rat pheochromocytoma line PC12, salvianolic acid Y has a 54.2% protection rate[1].
Salvianolic acid Y (TSL 1), a new phenolic acid with the same planar structure as salvianolic acid B, was isolated from Salvia officinalis. The structural elucidation and stereochemistry determination were achieved by spectroscopic and chemical methods, including 1D, 2D-NMR (1H-1H COSY, HMQC and HMBC) and circular dichroism (CD) experiments. The biosynthesis pathway of salvianolic acid B and salvianolic acid Y (TSL 1) was proposed based on structural analysis. The protection of PC12 cells from injury induced by H2O2 was assessed in vitro using a cell viability assay. Salvianolic acid Y (TSL 1) protected cells from injury by 54.2%, which was significantly higher than salvianolic acid B (35.2%). [1] |
| Enzyme Assay |
Activity in Vitro [1]
Rat pheochromocytoma PC12 cells were grown in tissue culture flasks in DMEM supplemented with 10% fetal bovine serum, and 100 U/mL penicillin and 100 U/mL streptomycin. The cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2. The culture media were changed every 2 days. The cells were inoculated to 96-well plates when grown to anastomose and treated with 10 µM salvianolic acid B and 10 µM Isosalvianolic acid Y for 6 h, respectively, followed by co-culture with 400 μM H2O2 for another 1 h. Cell survival was evaluated by the method of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide). The OD value was measured at λ = 570 nm by a spectrophotometer. The protection rate of tested compounds was calculated using the following equation: protection rate (%) = (cell viability of drug group − cell viability of model group)/(cell viability of control group − cell viability of model group) × 100% |
| References | |
| Additional Infomation |
A new phenolic acid with the same planar structure as salvianolic acid B, 4-[(1E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxphenyl)ethoxy]-3-oxo-1-propene-1-yl]-2-(3,4-dihydroxphenyl)-2S,3S-dihydro-7-hydroxy-, 3-[(1R)-1-carboxy-2-(3,4-dihydroxphenyl)ethyl] ester, was isolated from the extract of Salvia officinalis. The structural elucidation and stereochemistry determination were achieved by spectroscopic and chemical methods. The new compound was named salvianolic acid Y. For the In vitro biological activity test, our results suggest showed that salvianolic acid Y could rescue cell injury by H2O2, which was significantly better than salvianolic acid B. A plausible biogenetic pathway for salvianolic acid Y was proposed by our study.[1]
|
| Molecular Formula |
C36H30O16
|
|---|---|
| Molecular Weight |
718.613811969757
|
| Exact Mass |
718.153
|
| CAS # |
1638738-76-7
|
| PubChem CID |
5316299
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
52
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C(=CC=C(/C=C/C(=O)O[C@H](C(=O)O)CC3C=CC(=C(C=3)O)O)C=2[C@H](C(=O)O[C@H](C(=O)O)CC2C=CC(=C(C=2)O)O)[C@@H]1C1C=CC(=C(C=1)O)O)O
|
| InChi Key |
SNKFFCBZYFGCQN-BJMVGYQFSA-N
|
| InChi Code |
InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)/b10-5+
|
| Chemical Name |
2-[(E)-3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid
|
| Synonyms |
Salvianolic acid Y; 1638738-76-7; (2S)-2-[(E)-3-[(2R,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3916 mL | 6.9579 mL | 13.9158 mL | |
| 5 mM | 0.2783 mL | 1.3916 mL | 2.7832 mL | |
| 10 mM | 0.1392 mL | 0.6958 mL | 1.3916 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
